Treatment of pulmonary mucormycosis with adjunctive nebulized amphotericin B (MUCONAB trial): Results of an open-label randomized controlled trial.

Valliappan MuthuRatnakara Rao GogineniRitesh AgarwalKuruswamy Thurai PrasadInderpaul Singh SehgalSahajal DhooriaAshutosh N AggarwalShivaprakash Mandya RudramurthyHarkant SinghMandeep GargArunaloke Chakrabarti

Published in: Mycoses (2023)

Adjunctive NAB was safe but did not improve overall response at 6 weeks. A different dosing schedule or nebulized liposomal amphotericin B may still need evaluation. More research is needed to explore other treatment options for PM.

Keyphrases

randomized controlled trial
study protocol
particulate matter
clinical trial
pulmonary hypertension
air pollution
phase iii
phase ii
heavy metals
polycyclic aromatic hydrocarbons
risk assessment
open label
systematic review
tyrosine kinase
gestational age
water soluble